

## Web references

- w1 Frei M, Küster L, von Krosigk PG, Koch H, Küppers. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. *J Cardiovasc Pharmacol* 1994;**24**(Suppl 1):S25-S28
- w2 Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. *JAMA* 1990;**263**:1507-12
- w3 Petersen JR, Drabaek H, Gleeurup G, Mehlsen J, Petersen LJ, Winther K. ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension. *Angiology* 1996;**47**:233-40
- w4 Scholze J, Breitstadt A, Cairns V, Bauer B, Bender N, Priestley, et al. Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. *J Hypertens* 1993;**11**:217-21
- w5 Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. *Eur J Clin Pharmacol* 1990;**39**:327-32
- w6 Muiesan G, Agabiti-Rosei E, Buoninconti R, Cagli V, Carotti A, Corea L, et al. Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study. *J Hypertens* 1987;**5** (Suppl 5):S599-S602
- w7 Kayanakis JG, Baulac L. Comparative study of once-daily administration of captopril 50mg, hydrochlorothiazide 25mg and their combination in mild to moderate hypertension. *Br J Clin Pharmacol* 1987;**23** (Suppl 1):89S-92S
- w8 Wing LMH, Arnolda LF, Harvey PJ, Upton J, Molloy D, Bune AJC, et al. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. *J Hypertens* 1997;**15**:1503-10
- w9 MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. *Arch Intern Med* 1996;**156**:278-85
- w10 Chalmers JP, Morris MJ, Wing LMH, Cain MD, West MJ, Graham JR, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. *Aust NZ J Med* 1986;**16**:475-80
- w11 Chalmers JP, Korner PI, Tiller DJ, Bune AJ, Steiner JD, West MJ, et al. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension. *Med J Aust* 1976;**1**:650-3
- w12 Chalmers J, Horvath J, Tiller D, Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. *Lancet* 1976;**2**:328-31
- w13 McCorvey E, Wright JT, Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. *Clinical Pharmacology* 1993;**12**:300-5
- w14 Myers MG, de Champlain J. Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension. *Hypertension* 1983;**5**:591-6
- w15 Persson B, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. *Eur J Clin Pharmacol* 1996;**50**:259-64
- w16 Pool J, Cushman WC, Saini RK, Nwachuku CE, Battikha JP. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. *Am J Hypertens* 1997;**10**:117-23
- w17 Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. *Clin Ther* 1993;**15**:779-87
- w18 Moser M, Abraham PA, Bennett WM, Brachfeld N, Goodman RP, McKenney JM, et al. The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. *Clin Pharmacol Ther* 1991;**49**:322-9
- w19 Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. *J Human Hypertens* 1998;**12**:861-6
- w20 Canter D, Frank GJ, Knapp LE, Phelps M, Quade M, Texter M. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. *J Hum Hypertens* 1994;**8**:155-62
- w21 Fernández M, Madero R, González D, Camacho P, Villalpando J, Arriaga J. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. *Hypertension* 1994;**23** (Suppl I):I-207-10
- w22 Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. *J Hum Hypertens* 1994;**8**:283-8
- w23 Pordy RC. Cilazapril plus hydrochlorothiazide: improved efficacy without reduced safety in mild to moderate hypertension. *Cardiology* 1994;**85**:311-22
- 24 Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. *J Hum Hypertens* 1992;**6**:133-8
- w25 Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. *J Clin Pharmacol* 1995;**35**:182-8
- w26 Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. *Arch Fam Med* 1996;**5**:17-24

- w27 Goldberg MR, Rockhold FW, Offen WW, Dornseif BE. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. *Clin Pharmacol Ther* 1989;**46**:208-18
- w28 Pool PE, Applegate WB, Woehler T, Sandall P, Cady WJ. A randomized, controlled trial comparing diltiazem, hydrochlorothiazide, and their combination in the therapy of essential hypertension. *Pharmacotherapy* 1993;**13**:487-93
- w29 Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension. *Arch Intern Med* 1994;**154**:1461-9
- w30 Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. *Am J Hypertens* 1999;**12**:797-805
- w31 Jueng C, Halperin AK, Hasmimoto F, Callender K. Nifedipine GITS and hydrochlorothiazide in essential hypertension. *J Clin Hypertens* 1987;**3**:695-703
- w32 Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. *J Urol* 1982;**128**:903-7
- w33 Jounela AJ, Lilja M, Lumme J, Mörlin C, Hoyem A, Wessel-aas T, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. *Blood Press* 1994;**3**:231-5
- w34 Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. *Arch Intern Med* 1994;**154**:737-43
- w35 Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, et al. Dose response to chlorthalidone in patients with mild hypertension. *Clin Pharmacol Ther* 1978;**24**:192-8
- w36 Erwtaman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ.  $\beta$  Blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. *BMJ* 1984;**289**:406-9
- w37 Salvetti A, Magagna A, Innocenti P, Ponzanelli F, Cagianelli A, Cipriani M, et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study. *J Cardiovasc Pharmacol* 1991;**17**:332-5
- w38 Wing LMH, West MJ, Graham JR, Chalmers JP. Long-acting and short-acting diuretics in mild essential hypertension. *Clin Exp Hypertens* 1982;**A4**:1429-41
- w39 Bateman DN, Dean CR, Mucklow JC, Bulpitt CJ, Dollery CT. Atenolol and chlorthalidone in combination for hypertension. *Br J Clin Pharmacol* 1979;**7**:357-63
- w40 Morledge JH, Ettinger B, Aranda J, BcBarron F, Barra P, Gorwit J, et al. Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. *J Am Geriatr Soc* 1986;**34**:199-206
- w41 Cranston WI, Juel-Jensen BE. The effects of spironolactone and chlorthalidone on arterial pressure. *Lancet* 1962;**1**:1161-4
- w42 Ferrara LA, de Simone G, Mancini M, Fasano ML, Pasanisi F, Vallone G. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine. *Eur J Clin Pharmacol* 1984;**27**:525-8
- w43 Durel LA, Hayashi PJ, Weidler DJ, Schneiderman N. Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. *J Clin Pharmacol* 1992;**32**:564-70
- w44 Bradley K, Flack JM, Belcher J, Elmer P, Miller P, Grimm R. Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. *Am J Hypertens* 1993;**6**:636-9
- w45 Moser M. Low-dose diuretic therapy for hypertension. *Clin Ther* 1986;**8**:554-62
- w46 McFate Smith WM, Feigal DW, Furberg CD, Greenlick M, Kuller L, Perry HM, et al. Use of diuretics in treatment of hypertension in the elderly. *Drugs* 1986;**31**:154-64
- w47 Hall WD, Weber MA, Ferdinand K, Flamenbaum W, Marbury T, Jain AK, et al. Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. *J Hum Hypertens* 1994;**8**:571-5
- w48 Schaller M, Waeber B, Brunner HR. Double-blind comparison of indapamide with a placebo in hypertensive patients treated by practicing physicians. *Clin Exp Hypertens* 1985;**A7**:985-94
- w49 Fiddes R, Blumenthal J, Dawson JE, Dyckman E, Hammond PGS, Harris S, et al. Evaluation of indapamide 1.25mg once daily in elderly patients with mild to moderate hypertension. *J Hum Hypertens* 1997;**11**:239-44
- w50 Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. *J Cardiovasc Pharmacol* 1993;**22** (Suppl 6):S78-S86
- w51 Chalmers JP, Wing LMH, Grygiel JJ, West MJ, Graham JR, Bune AJ. Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting. *Eur J Clin Pharmacol* 1982;**22**:191-6
- w52 Taylor DR, Constable J, Sonnekus M, Milne FJ. Effect of indapamide on serum and red cell cations, with and without magnesium supplementation, in subjects with mild hypertension. *S Afr Med J* 1988;**74**:272-6
- w53 Weidler D, Jallad NS, Curry C, Ferdinand K, Jain AK, Schnaper HW, et al. Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension. *J Clin Pharmacol* 1995;**35**:45-51
- w54 Ambrosioni E, Safar M, Degaute JP, Malin PL, MacMahon M, Pujol DR, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. *J Hypertens* 1998;**16**:1677-84
- w55 Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide. *J Hypertens* 2000;**18**:317-25

- w56 Carlsen JE, Køber L, Torp-Pedersen, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. *BMJ* 1990;**300**:975-8
- w57 Christiansen C, Christensen MS, Hagen C, Stocklund KE, Transbøl I. Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women. *Acta Obstet Gynecol Scand* 1981;**60**:407-412
- w58 Horvath JS, Caterson RJ, Collett P, Duggin GG, Kelly DH, Tiller DJ. Labetalol and bendrofluazide: comparison of their antihypertensive effects. *Med J Aust* 1979;**1**:626-8
- w59 Webster J, Dollery CT, Hensby CN. Circulating prostacyclin concentrations may be increased by bendrofluazide in patients with essential hypertension. *Clin Sci* 1980;**59** (Suppl 6):125s-128s
- w60 Wilcox RG. Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. *BMJ* 1978;**2**:383-5
- w61 Curry CL, Harris R, MacKay JH, Nugent CA, Ryan J, Schnaper, et al. Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension. *Clin Ther* 1986;**9**:47-62
- w62 Fernandez PG, Zachariah PK, Bryant DG, Missan SS. Antihypertensive efficacy of  $\alpha$ -methyldopa, chlorothiazide and Supres-150 ( $\alpha$ -methyldopa-chlorothiazide). *Can Med Assoc J* 1980;**123**:284-7
- w63 McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopentiazide. *BMJ* 1988;**297**:95-8
- w64 Chrysant SG, Chappel C, Farnham J, Levin B, Lueg M, McCluskey D, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. *J Clin Pharmacol* 1992;**32**:61-65
- w65 Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen. *J Hypertens* 1991;**9**:1063-8
- w66 Verdecchia P, Gatteschi C, Benemio G, Boldrini F, Guerrieri M, Porcellati C. Duration of the antihypertensive action of atenolol, enalapril and placebo. *Int J Clin Pharmacol Ther Toxicol* 1988;**26**:570-4
- w67 Gostick NK, Mayhew SR, Million R, Sagar D, Suxena SR, Igram DF, et al. A dose-response study of atenolol in mild to moderate hypertension in general practice. *Curr Med Res Opin* 1977;**5**:179-84
- w68 Cilliers AJ. Atenolol as primary therapy in previously untreated hypertensives and as an adjuvant to other therapy. *S Afr Med J* 1979;**55**:321-4
- w69 Baez MA, Garg DC, Jallad NS, Weidler DJ. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. *Br J Clin Pharmacol* 1986;**21** (Suppl 1):63S-67S
- w70 Maclean D, Mitchell ET, Lewis R, Irvine N, McLay S, McEwen J, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. *Br J Clin Pharmacol* 1990;**29**:455-63
- w71 Van Nueten L, Taylor FR, Robertson JIS. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. *J Hum Hypertens* 1998;**12**:135-40
- w72 Hansson L, Åberg H, Karlberg BE, Westerlund A. Controlled study of atenolol in treatment of hypertension. *BMJ* 1975;**2**:367-70
- w73 Lange-Andersen KL, Ottmann W, Piatkowski W, Green KA. Working ability and exercise tolerance during treatment of mild hypertension. *Int Arch Occup Environ Health* 1985;**56**:49-55
- w74 Tonkin AL, Wing LMH, Russell AE, West MJ, Bune AJC, Morris MJ, et al. Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. *J Hypertens* 1990;**8**:1015-8
- w75 Streufert S, DePadova A, McGlynn T, Pogash R, Piasecki M. Impact of  $\beta$ -blockade on complex cognitive functioning. *Am Heart J* 1988;**116**:311-4
- w76 Wing LMH, Chalmers JP, West MJ, Russell AE, Morris MJ, Cain MD. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. *Clin Exp Hypertens* 1988;**10**:119-33
- w77 Ekblom T, Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Wester P. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. *J Hypertens* 1991;**10**:1525-9
- w78 Saul P, Jones BP, Edwards KG, Tweed JA. Randomized comparison of atenolol and placebo in the treatment of anxiety: a double-blind study. *Eur J Clin Pharmacol* 1985;**28**:109-110
- w79 Lyons D, Fowler G, Webster J, Hall ST, Petrie JC. An assessment of lacidipine and atenolol in mild to moderate hypertension. *Br J Clin Pharmacol* 1994;**37**:45-51
- w80 Tötterman K, Groop L, Groop P, Kala R, Tolppanen, Fyhrquist F. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. *Eur J Clin Pharmacol* 1984;**26**:13-7
- w81 Jeffers TA, Webster J, Petrie JC. Atenolol once-daily in hypertension. *Br J Clin Pharmacol* 1977;**4**:523-7
- w82 Clement DL, Bogaert MG, Pannier R. Effect of beta-adrenergic blockage on blood pressure variation in patients with moderate hypertension. *Eur J Clin Pharmacol* 1977;**11**:325-7
- w83 Clement DL, De Pue NY, Packet L. Effect of calcium antagonists on ambulatory blood pressure and its variations. *J Cardiovasc Pharmacol* 1987;**10** (Suppl 10):S117-S119
- w84 Petrie C, Jeffers TA, Robb OJ, Scott AK, Webster J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. *BMJ* 1980;**1**:1573-4
- w85 Houston MC, Burger C, Hays JT, Nadeau J, Swift L, Bradley CA, et al. The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. *Am Heart J* 1990;**120**:172-9
- w86 Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. *Lancet* 1987;**2**:650-

- w87 Wilcox RG, Hampton JR. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. *Br Heart J* 1981;**46**:498-502
- w88 Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. *BMJ* 1991;**303**:1100-4
- w89 Broekman CPM, Haensel SM, Ven de Ven LLM, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. *J Sex Marital Ther* 1992;**18**:325-31
- w90 Van de Ven LLM, Mouthaan BJ, Hoes MJ. Treatment of hyperventilation syndrome with bisoprolol: a placebo-controlled clinical trial. *J Psychosom Res* 1995;**39**:1007-13
- w91 Tseng C, Chiang F, Hsu K, Tseng Y, Hu W, Chen J, et al. Short-term efficacy and safety of bisoprolol in treatment of patients with mild-to-moderate hypertension - A two-center, double-blind study in Taiwan. *Acta Cardiologica Sinica* 1993;**9**:155-60
- w92 Davidov ME, Singh SP, Vlachakis ND, Blumenthal JB, Simon JS, Bryzinski JS, et al. Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension. *Clin Cardiol* 1994;**17**:263-268
- w93 Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. *Am J Cardiol* 1991;**68**:61-4
- w94 Williams RL, Goyle KK, Herman TS, Rofman BA, Ruoff GE, Hogan LB. Dose-dependent effects of betaxolol in hypertension: a double-blind multicenter study. *J Clin Pharmacol* 1992;**32**:360-7
- w95 Ameling EH, de Korte DF, Man in 't Veld AJ. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. *J Cardiovasc Pharmacol* 1991;**18**:752-60
- w96 Salonen JT, Palminteri R. Comparison of two doses of betaxolol and placebo in hypertension: a randomised, double-blind cross-over trial. *Eur J Clin Pharmacol* 1982;**23**:491-4
- w97 Gudbjornsdottir S, Fowelin J, Elam M, Attvall S, Bengtsson BA, Marin P, et al. The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormone levels in hypertensive subjects. *Eur J Clin Invest* 1997;**27**:29-35
- w98 Groop L, Tötterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in hypertensive, non-diabetic patients. *Acta Med Scand* 1983;**213**:9-14
- w99 Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. *J Intern Med* 1994;**235**:335-41
- w100 Jäättelä A, Baandrup S, Houtzagers J, Westergren G. The efficacy of low dose metoprolol CR/ZOK in mild hypertension and in elderly patients with mild to moderate hypertension. *J Clin Pharmacol* 1990;**30** (Suppl):S66-S71
- w101 Lepäntalo MJA, Tötterman KJ. Lower limb haemodynamics during antihypertensive treatment with metoprolol and propranolol. *Int Angiol* 1985;**4**:225-8
- w102 MacMahon S, MacDonald GJ, Bernstein L, Andrews G, Blacket RB. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. *Lancet* 1985;**1**:1233-6
- w103 Reybrouck T, Amery A, Fagard R, Jousten P, Lijnen P, Meulepas E. Beta-blockers: once or three times a day? *BMJ* 1978;**1**:1386-8
- w104 Vandongen R, Margetts B, Deklerk N, Beilin LJ, Rogers P. Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol. *Br J Clin Pharmacol* 1986;**21**:627-32
- w105 Trafford JAP, Latta D, Little PS, Parsley J, Ankier SI. A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. *Curr Med Res Opin* 1989;**11**:550-6
- w106 Kimura S, DeQuattro V, Hernandez PH, Lee DD. Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension. *Am J Cardiol* 1988;**62**:751-4
- w107 Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. *Br J Clin Pharmacol* 1980;**9**:209-12
- w108 Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS. A dose-response trial of nebivolol in essential hypertension. *J Hum Hypertens* 1997;**11**:139-44
- w109 Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral *d*- and *l*-nebivolol in hypertensive patients. *Eur J Clin Pharmacol* 1996;**51**:259-64
- w110 van Merode T, van Bortel L M, Smeets FA, Mooij JM, Bohm RO, Rahn KH, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. *J Hypertens* 1989;**7** (suppl 6):S262-3
- w111 Glasscock RJ, Weitzman RE, Bennett CM, Maxwell M, Hamilton B, Winer N, et al. Pindolol: effects on blood pressure and plasma renin activity. *Am Heart J* 1982;**104**:421-5
- w112 Hamilton BP, Hamilton J, Kirkendall WM. Pulmonary function in hypertensive patients treated with pindolol: a report of two studies. *Am Heart J* 1982;**104**:432-7
- w113 Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. *Biol Psychiatry* 1999;**45**:1170-7
- w114 Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. *J Clin Psychopharmacol* 1998;**18**:441-6
- w115 Pearson RM, Bulpitt CJ, Havard CWH. Biochemical and haematological changes induced by tienilic acid

- combined with propranolol in essential hypertension. *Lancet* 1979;**1**:697-9
- w116 Dargie H, Cleland J, Findlay I, Murray G, McInnes G. Combination of verapamil and beta-blockers in systemic hypertension. *Am J Cardiol* 1986;**57**:80D-82D
- w117 McInnes GT, Findlay IN, Murray G, Cleland JGF, Dargie HJ. Cardiovascular responses to verapamil and propranolol in hypertensive patients. *J Hypertens* 1985;**3** (Suppl 3):S219-21
- w118 Galloway DB, Glover SC, Hendry WG, Logie AW, Petrie JC, Smith MC, et al. Propranolol in hypertension: a dose-response study. *BMJ* 1976;**2**:140-2
- w119 Hudson CFE. An evaluation of once daily long acting propranolol hydrochloride (Inderal LA and Half-Inderal LA) in the treatment of anxiety. A double-blind placebo-controlled general practice study. *Br J Clin Pract* 1988;**42**:419-26
- w120 Moleur P, Peyrieux JC, Luciani J, David D, Boissel JP. Bopindolol in the treatment of moderate hypertension: a dose-response study. *Fundam Clin Pharmacol* 1988;**2**:431-40
- w121 Adsett CA, Bellissimo A, Mitchell A, Wilczynski N, Haynes RB. Behavioral and physiological effects of a beta-blocker and relaxation therapy on mild hypertensives. *Psychosom Med* 1989;**51**:523-6
- w122 Dupont AG, Vanderniepen P, Bossuyt AM, Jonckheer MH, Six RO. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function. *Br J Clin Pharmacol* 1985;**20**:93-99
- w123 Casadei B, Conway J, Coats AJS, Bird R. Antihypertensive effect of carvedilol: a preliminary dose-response study. *Clinical Investigator* 1992;**70** (Suppl):S37-S38
- w124 Dupont AG, Van der Niepen P, Taeymans Y, Ingels M, Piepsz A, Bossuyt AM, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. *J Cardiovasc Pharmacol* 1987;**10** (Suppl 11):S130-S136
- w125 Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. *N Eng J Med* 1998;**338**:784-90
- w126 Chrysant SG, Brown RD, Kem DC, Brown JL. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril. *Clin Pharmacol Ther* 1983;**33**:741-6
- w127 Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise induced angina and ST segment depression in patients with microvascular angina. *J Am Coll Cardiol* 1987;**23**:652-7
- w128 Küppers HE, Jäger BA, Luszick JH, Gräve, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. *J Hypertens* 1997;**15**:93-7
- w129 Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. *Clin Pharmacol Ther* 1991;**50**:96-106
- w130 Forette F, Handfield-Jones R, Henry-Amar M, Fouchard M, Bouchacourt P, Hervy M, et al. Rationale for ACE inhibition in the elderly: treatment of arterial hypertension with enalapril. *Gerontology* 1987;**33**:9-16
- w131 van Baak MA, Mooij JMV, Wijnen JAG, Tan FS. Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension. *Clin Pharmacol Ther* 1991;**50**:221-7
- w132 Bergstrand R, Herlitz H, Johansson S, Berglund G, Vedin A, Wilhelmsson C, et al. Effective dose range of enalapril in mild to moderate essential hypertension. *Br J Clin Pharmacol* 1985;**19**:605-11
- w133 Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton G, Fox KM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. *Br Heart J* 1989;**62**:112-7
- w134 Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. *Am J Hypertens* 1989;**2**:352-4
- w135 Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. *Am J Cardiol* 1997;**79**:431-5
- w136 Cushman WC, Cohen JD, Jones RP, Marbury TC, Rhoades RB, Smith LK. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. *Am J Hypertens* 1998;**11**:23-30
- w137 Whelton A, Dunne B, Glazer N, Kostis JB, Miller WE, Rector DJ, et al. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. *J Hum Hypertens* 1992;**6**:325-31
- w138 Levine JH, Ferdinand KC, Cargo P, Laine H, Lefkowitz M. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. *Am J Hypertens* 1995;**8**:494-9
- w139 Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. *J Hypertens* 1996;**14**:1147-51
- w140 Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. *Hypertension* 1995;**25**:1345-50
- w141 Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. *Kidney Int* 2000;**57**:601-6
- w142 Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. *Hypertension* 1995;**25**:37-46
- w143 Smith DHG, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with

- mild to moderate hypertension. *J Clin Pharmacol* 2000;**40**:1380-90
- w144 Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. *J Hum Hypertens* 1997;**11** (Suppl 2):S61-62
- w145 Simon G, Morioka S, Snyder DK, Cohn JN. Increased renal plasma flow in long-term enalapril treatment of hypertension. *Clin Pharmacol Ther* 1983;**34**:459-65
- w146 Sassano P, Chatellier G, Alhenc-Gelas F, Corvol P, Menard J. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. *Am J Med* 1984;**77**(suppl 2A):18-22
- w147 Bilan A, Chibowska M, Palusinski R, Witzczak, Ostrowski S, Makaruk B, et al. Enalapril (10 mg/day) in systemic sclerosis. *Adv Exp Med Biol* 1999;**455**:285-8
- w148 Applegate WB, Cohen JD, Wolfson P, Davis A, Green S. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. *Am J Cardiol* 1996;**78**:51-5
- w149 Gerritsen TA, Bak AAA, Stolk RP, Jonker JJC, Grobbee DE. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. *J Hypertens* 1998;**16**:689-96
- w150 Morgan TO, Morgan O, Anderson A. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males. *Clin Exp Pharmacol Physiol* 1995;**22**:778-80
- w151 Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaik S, Martin FIR. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. *Metabolism* 1998;**47** (suppl 1):12-15
- w152 Luccioni R, Frances Y, Gass R, Gilgenkrantz JM. Evaluation of the dose-effect relationship of perindopril in the treatment of hypertension. *Clin Exp Hypertens* 1989;**A11**:521-34
- w153 West JNW, Smith SA, Stallard TJ, Littler WA. Effects of perindopril on ambulatory intra-arterial blood pressure, cardiovascular reflexes and forearm blood flow in essential hypertension. *J Hypertens* 1989;**7**:97-104
- w154 Louis WJ, Workman BS, Conway EL, Worland P, Rowley K, Drummer O, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. *J Cardiovasc Pharmacol* 1992;**20**:505-11
- w155 Chrysant SG, McDonald RH, Wright JT, Barden PL, Weiss RJ. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. *Clin Pharmacol Ther* 1993;**53**:479-84
- w156 Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24h after dosing. *Am J Cardiol* 1996;**12**:1191-6
- w157 Overlack A, Adamczak M, Bachmann W, Bönner G, Bretzel RG, Derichs R, et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. *Am J Med* 1994;**97**:126-34
- w158 Cheung R, Lewanczuk RZ, Rodger NW, Huff MW, Oddou-Stock P, Botteri F, et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. *Int J Clin Pract* 1999;**53**:584-92
- w159 Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, Rossetti M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. *J Hypertens* 1987;**5** (Suppl 4):S139-S142
- w160 Schoenberger JA, Wilson DJ. Once-daily treatment of essential hypertension with captopril. *J Clin Hypertens* 1986;**4**:379-87
- w161 Conway J, Way B, Boon N, Somers V. Is the antihypertensive effect of captopril influenced by the dosage frequency? A study with ambulatory monitoring. *J Hum Hypertens* 1988;**2**:123-6
- w162 Lavessaro G, Ladetto PE, Valente M, Stramignoni D, Zanna C, Assogna G, et al. Ketanserin and captopril interaction in the treatment of essential hypertensives. *Cardiovasc Drugs Ther* 1990;**4**:119-22
- w163 Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. *Arch Intern Med* 1984;**144**:1947-53
- w164 Salvetti A, Circo A, Raciti S, Gulizia M, Cardillo R, Miceli S, et al. Captopril at 50mg as well as at 100mg once a day reduces blood pressure for up to 24h: a double-blind randomized crossover study in mild to moderate hypertensives. *J Hypertens* 1988;**6** (Suppl 4):S666-S668
- w165 Wiggam MI, Hunter SJ, Atkinson AB, Ennis CN, Henry JS, Browne JN, et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. *J Hypertens* 1998;**16**:1651-7
- w166 Drayer JIM, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. *Hypertension* 1983;**5** (Suppl III):III108-13
- w167 Insua A, Ribstein J, Mimran A. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. *Postgrad Med J* 1988;**64** (Suppl 3):59-62
- w168 Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. *Hypertension* 1995;**26**:124-30
- w169 Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. *Lancet* 1998;**352**:1978-81
- w170 DeQuattro V, Lee D. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. *Am J Hypertens* 1997;**10** (Suppl):138S-145S

- w171 Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure. *Am J Hypertens* 1997;**10**:492-9
- w172 De Bruijn JHB, Orofiamma BA, Pauly NC. Efficacy and tolerance of trandolapril (0.5-2mg) administered for 4 weeks in patients with mild-to-moderate hypertension. *J Cardiovasc Pharmacol* 1994;**23** (Suppl 4):S60-S64
- w173 Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. *Am J Hypertens* 1998;**11**:322-7
- w174 Pritchard G, Lyons D, Webster J, Petrie JC, MacDonald TM. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? *Br J Clin Pharmacol* 1997;**44**:145-9
- w175 Kohlmann O, Jardim PCBV, Oigman W. Brazilian multicenter on efficacy and tolerability in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring. *Arq Bras Cardiol* 1999;**72**:553-7
- w176 Mancia G, De Cesaris R, Fogari R, Lattuada S, Montemurro G, Palombo C, et al. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure. *Am J Cardiol* 1992;**70**:60D-66D
- w177 Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design. *Br J Clin Pharmacol* 1998;**45**:491-5
- w178 Mroczek WJ, Klein J, Burris JF. Dose-finding study of cilazapril (inhibace) in patients with uncomplicated essential hypertension. *Clin Exp Hypertens* 1991;**A13**:1415-32
- w179 Prager G, Klein P, Schmitt M, Prager R. Antihypertensive efficacy of cilazapril 2.5 and 5.0mg once-daily versus placebo on office blood pressure and 24-hour blood pressure profile. *J Cardiovasc Pharmacol* 1994;**24** (Suppl 3):S93-S99
- w180 Kobrin I, Güntzel P, Viskoper R, Paran E, Zimlichman R. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension. *Drugs* 1991;**41**:31-6
- w181 Güntzel P, Kobrin I, Pasquier C, Zimlichman R, Viskoper JR. The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients. *J Cardiovasc Pharmacol* 1991;**17**:8-12
- w182 Lacourcière Y, Leenen F, Rangno R, Spence JD, Lenis JH, Myers MG. Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy. *Can J Cardiol* 1994;**10**:605-10
- w183 Fernandez PG, Bolli P, Lee C. The 24h blood pressure responses of hypertensives to a once-a-day cilazapril regimen. *Can J Cardiol* 1990;**6**:53-8
- w184 Krum H, Jackson B, Conway EL, Howes LG, Johnston CI, Louis WJ. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclophosphamide. *J Cardiovasc Pharmacol* 1992;**20**:451-7
- w185 White WB, McCabe EJ, Hager WD, Schulman P. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise and ambulatory blood pressure. *Clin Pharmacol Ther* 1988;**44** (Suppl 3):173-8
- w186 Poirier L, Pyzyk M, Provencher P, Lacourcière. Comparative effects of 2.5 and 5mg cilazapril versus placebo on daily blood pressure load. *Am J Hypertens* 1991;**4**:913-5
- w187 Burris JF. The effect of ramipril on ambulatory blood pressure: a multicenter study. *J Cardiovasc Pharmacol* 1991;**18** (Suppl 2):S131-3
- w188 McCarron D. 24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. *Clin Cardiol* 1991;**14**:737-42
- w189 Schnaper HW. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension. *J Cardiovasc Pharmacol* 1991;**18** (Suppl 2):S128-S130
- w190 Homuth V, Faulhaber H, Loose U, Löffler K, Luft FC. Usefulness of piritanide plus ramipril for systemic hypertension: a multicenter trial. *Am J Cardiol* 1993;**72**:666-71
- w191 Villamil AS, Cairns V, Witte PU, Bertolasi CA. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo. *Am J Cardiol* 1987;**59**:110D-114D
- w192 Kahan T, Eliasson K. The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension. *Am J Hypertens* 1999;**12**:1188-94
- w193 Scholze J, Bauer B, Massaro J. Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. *Clin Exp Hypertens* 1999;**21**:1447-62
- w194 Chan P, Lin C, Tomlinson B, Lin T, Lee Y. Additive effects of diltiazem and lisinopril in treatment of elderly patients with mild-to-moderate hypertension. *Am J Hypertens* 1997;**10**:743-9
- w195 Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. *J Hum Hypertens* 1997;**11**:483-9
- w196 Thürig C, Böhlen L, Schneider M, de Courten M, Shaw SG, Riesen W, et al. Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. *Eur J Clin Pharmacol* 1995;**49**:21-6
- w197 Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, et al. Lisinopril administration improves insulin action in aged patients with hypertension. *J Hum Hypertens* 1995;**9**:541-6
- w198 Tomei R, Rossi L, Carbonieri E, Franceschini L, Molon G, Zardini P. Antihypertensive effect of lisinopril assessed by 24-hour ambulatory monitoring: a double-blind, placebo-controlled, cross-over study. *J Cardiovasc Pharmacol* 1992;**19**:911-14

- w199 Polónia J, Martins L, Macedo F, Faria DB, Simões, Brandão F, et al. Lisinopril and diltiazem reduce left ventricular mass without changing blood pressure in normotensive subjects with exaggerated blood pressure response to exercise. *Rev Port Cardiol* 1996;**15**:185-93
- w200 Gomez JH, Cirillo VJ, Sromovsky JA, Otterbein ES, Shaw WC, Rush JE, et al. Lisinopril dose-response relationship in essential hypertension. *Br J Clin Pharmacol* 1989;**28**:415-20
- w201 Cuspidi C, Lonati L, Sampieri L, Leonetti G, Muiesan ML, Agabiti-Rosei E, et al. Lack of effect of short-term lisinopril administration on left ventricular filling dynamics in hypertensive patients with diastolic dysfunction. *Blood Pressure* 1997;**6**:307-12
- w202 Lee AFC, Dick JBC, Bonnar CE, Struthers AD. Lisinopril improves arterial function in hyperlipidaemia. *Clin Sci* 1999;**96**:441-8
- w203 Maclean D. Quinapril: a double-blind, placebo-controlled trial in essential hypertension. *Angiology* 1989;**40**:370-81
- w204 Säynävalampi P, Pörsti I, Pörsti P, Nurmi A, Seppälä E, Manninen V, et al. Effects of the converting enzyme inhibitor quinapril on blood pressure, renin-angiotensin system and prostanoids in essential hypertension. *J Cardiovasc Pharmacol* 1988;**12**:88-93
- w205 Gupta RK, Kjeldsen SE, Motley E, Weder AB, Sweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. *J Cardiovasc Pharmacol* 1991;**17**:13-9
- w206 Kjeldsen SE, Gupta RK, Krause L, Weder AB, Julius S. Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril. *Am Heart J* 1992;**123**:1433-8
- w207 Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. *Diabetes Care* 1997;**20**:355-361
- w208 Ford NF, Fulmor IE, Nichola PS, Alpin PG, Herron JM. Fosinopril monotherapy: relationship between blood pressure reduction and time of administration. *Clin Cardiol* 1993;**16**:324-30
- w209 Anderson RJ, Duchin KL, Gore RD, Herman TS, Michaels RS, Nichola PS, et al. Once-daily fosinopril in the treatment of hypertension. *Hypertension* 1991;**17**:636-42
- w210 Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. *Clin Ther* 1990;**12**:520-33
- w211 Guitard C, Lohmann FW, Alfiero R, Ruina M, Alvisi V. Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension. *Cardiovasc Drugs Ther* 1997;**11**:449-57
- w212 Guitard C, Sassano P, Tzincoca C, Duchiez J, Safar ME. Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension. *Blood Press* 1994;**3** (suppl 2):61-8
- w213 Guitard C, Alvisi V, Maibach E, Franck J, Cocco G, Boxho G, et al. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension. *Blood Press* 1994;**3** (suppl 2):81-7
- w214 Fairhurst GJ. A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. *Blood Press* 1994;**3** (suppl 2):77-80
- w215 Frishman WH, Ram CVS, McMahon FG, Chrysant SG, Graff A, Kupiec JW, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. *J Clin Pharmacol* 1995;**35**:1060-6
- w216 Kuschnir E, Acuña E, Sevilla D, Vasquez J, Bendersky M, Resk J, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 10 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. *Clin Ther* 1996;**18**:1213-24
- w217 Koch B, Oparil S, Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. *J Human Hypertens* 1999;**13**:337-42
- w218 Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. *Am J Hum Hypertens* 2000;**13**:1045-8
- w219 Christensen PK, Lund S, Parving H-H. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. *Kidney Int* 2001;**60**:1435-42
- w220 Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. *J Hum Hypertens* 1997;**11**:S55-6
- w221 Meineke I, Feltkamp H, Högemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. *Eur J Clin Pharmacol* 1997;**53**:221-8
- w222 Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin-II antagonist, provides dose dependent antihypertensive effect. *J Hum Hypertens* 1997;**11**:S49-53
- w223 Farsang C, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. *Clin Drug Invest* 2001;**21**:17-23
- w224 Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. *Am J Hypertens* 1999;**12**:1181-7
- w225 Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin-II antagonist, in comparison with losartan. *Blood Press* 1998;**7**:53-9

- w226 Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, et al. Effects of candesartan cilexetil in patients with systemic hypertension. *Am J Cardiol* 1998;**82**:961-5
- w227 Bell TP, DeQuattro V, Lasseter KC, Ruff D, Hardison JD, Cushing D, et al. Effective dose range of candesartan cilexetil for systemic hypertension. *Am J Cardiol* 1999;**83**:272-5
- w228 Zuschke CA, Keys I, Munger MA, Carr AA, Marinides GN, Flanagan TL, et al. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. *Clin Ther* 1999;**21**:464-74
- w229 Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, et al. A comparison of angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. *Am J Hypertens* 1999;**12**:414-7
- w230 Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. *Clin Ther* 1996;**18**:797-810
- w231 Neutel J, Weber M, Pool J, Smigh D, Fitzsimmons S, Chiang Y-T, et al. Valsartan, a new angiotensin-II antagonist: antihypertensive effects over 24 hours. *Clin Ther* 1997;**19**:447-58
- w232 Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. *Clin Ther* 1998;**20**:1106-15
- w233 Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin-II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. *Am J Hypertens* 1998;**11**:445-53
- w234 Mallion M, Siche JP, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin-II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. *J Hum Hypertens* 1999;**13**:657-64
- w235 Paolisso G, Tagliamonte MR, Gambardella A, Manzella D, Gualsiero P, Varricchio G, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. *J Hum Hypertens* 1997;**11**:307-12
- w236 Fagard R, Lijnen P, Pardaens K, Thijs L, Vinck W. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. *J Hum Hypertens* 2001;**15**:161-7
- w237 Cheetham C, O'Driscoll G, Standon K, Taylor R, Green D. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. *Clin Sci* 2001;**100**:13-7
- w238 Pancera P, Persciuttini B, Sansone S, Montagna L, Paluani F, Covi G, et al. Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. *J Hypertens* 1999;**17**:513-21
- w239 Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. *J Hypertens* 1995;**13**:S29-33
- w240 Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50mg and losartan 50mg titrated to 100mg in patients with essential hypertension. *Blood Press* 1997;**6**:35-43
- w241 Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin-II antagonist. *J Hypertens* 2001;**19**:S41-8
- w242 Pool JL, Glazer R, Chiang Y-T, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin-II receptor blocker. *J Hum Hypertens* 1999;**13**:275-81
- w243 Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Efficacy and tolerability of irbesartan, an angiotensin-II receptor antagonist, in primary hypertension. *Clin Drug Invest* 1998;**3**:217-27
- w244 Fogari R, Ambrosoli S, Corradi L, Esposti ED, Mos L, Nami R, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. *J Hum Hypertens* 1997;**15**:1511-8
- w245 Pool JL, Guthrie RM, Littlejohn TW, Raskin P, Shephard AMM, Weber A, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. *Am J Hypertens* 1998;**11**:462-70
- w246 Benetos A, Gautier S, Laflèche A, Topouchian Jm, Frangin G, Girerd X, et al. Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans. *J Vasc Res* 2000;**37**:8-15
- w247 McGill JB, Reilly P. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomised double-blind, placebo-controlled, parallel-group trial. *Clin Ther* 2001;**23**:833-50
- w248 Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT<sub>1</sub> receptor antagonist telmisartan in patients with mild to moderate hypertension. *Adv Therapy* 1998;**15**:206-17
- w249 Neutel JM, Buckalew V, Chrysant SG, Mroczek WJ, Ruff DA, Weber M. Efficacy and tolerability of tasosartan, a novel angiotensin-II receptor blocker: results from a 10-week, double-blind, placebo controlled, dose-titration study. *Am Heart J* 1999;**137**:118-25
- w250 Feldman R, Chattman MS, Lonigro A, Sievers RJ. Tasosartan in patients with essential hypertension: a randomized, double-blind, dose-titration study. *Adv Therapy* 1997;**14**:290-303
- w251 Rhéaume C, Waib PH, Lacourcière Y, Cléroux J. Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. *J Hypertens* 1998;**16**:2085-9
- w252 Lacourcière Y, Pool JL, Svetkey L, Gradman AH, Laroche P, de Champlain J, et al. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. *Am J Hypertens* 1998;**11**:454-61
- w253 Gradman AH, Gray J, Maggiasimo F, Punzi H, White WB. Assessment of once-daily eprosartan, an

- angiotensin-II antagonist, in patients with systemic hypertension. *Clin Ther* 1999;**21**:442-53
- w254 Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. *J Hypertens* 1999;**17**:129-36
- w255 White WB, Anwar YA, Mansoor GA, Sica DA. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. *Am J Hypertens* 2001;**14**:1248-55
- w256 Schmitz A, Pedersen MM, Mogensen CE. Effects of felodipine on urinary albumin excretion and metabolic control in hypertensive non-insulin-dependent diabetics. *Am J Hypertens* 1990;**3**:611-617
- w257 Campbell LM, Cowen KJ, Cranfield FR, Goves JR, Jones DF, Lees CTW, et al. Felodipine-ER once daily as monotherapy in hypertension. *J Cardiovasc Pharmacol* 1990;**15**:569-573
- w258 Cooperative Study Group. Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. *Drugs* 1987;**34**(Suppl 3):139-148
- w259 Crozier IG, Ikram H, Nicholls MG, Low CJS. Twenty-four hour profile of the hypotensive action of felodipine in essential hypertension. *Cardiovasc Drugs Ther* 1990;**4**:439-442
- w260 Fagan TC. Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients. *J Am Geriatr Soc* 1997;**45**:712-717
- w261 Hamilton DV, Barnes PC, Bowles RML, Rajaratnam DV, Comerford MB, Ginks WR, et al. Monotherapy with felodipine, a new calcium antagonist, in mild and moderate hypertension. *J Cardiovasc Pharmacol* 1987;**10**(supplS):S111-S113
- w262 Hosie J, Mulder AW, Westberg B. Felodipine once daily in elderly hypertensives. *J Hum Hypertens* 1991;**5**:49-53
- w263 Liedholm H, Melander A. A placebo-controlled dose-response study of felodipine extended release in hypertensive patients. *J Cardiovasc Pharmacol* 1989;**14**:109-113
- w264 Madsen JK, Zachariae H, Pedersen EB. Effects of the calcium antagonist felodipine on renal aerodynamics, tubular sodium handling, and blood pressure in cyclosporin-treated dermatological patients. *Nephrol Dial Transplant* 1997;**12**:480-484
- w265 McGrath BP, Watts RW, Elmfeldt DB. Clinical equivalence of two tablet formulations of felodipine. *Eur J Clin Pharmacol* 1995;**49**:169-172
- w266 Pannarale G, Puddu PE, Monti F, Irace L, Bentivoglio M, Collauto F, et al. Twenty-four antihypertensive efficacy of felodipine 10 mg extended-release: the Italian inter-university study. *J Cardiovasc Pharmacol* 1996;**27**:255-261
- w267 Porcellati C, Verdecchia P, Gatteschi C, Benemio G, Guerrieri M, Boldrini F, et al. Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension. *Eur J Clin Pharmacol* 1989;**37**:555-557
- w268 Bonaduce D, Canonico V, Petretta M, Forgione L, Ianniciello A, Cavallaro V, et al. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study. *Eur J Clin Pharmacol*;1997;**53**:95-100
- w269 van Ree JW, van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. *J Hum Hypertens* 1996;**10**:613-618
- w270 Weber MA, Goldberg AI, Faisons EP, Lipschutz K, Shapiro DA, Nelson EB, et al. Extended-release felodipine in patients with mild to moderate hypertension. *Clin Pharmacol Ther* 1994;**55**:346-352
- w271 Wester A, Lorimer AR, Westberg B. Felodipine extended release in mild to moderate hypertension. *Curr Med Res Opin* 1991;**12**:275-281
- w272 Bossini A, Di Veroli C, Cavallotti G, Cagli V. Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo. *Br J Clin Pharmacol* 1990;**30**:567-571
- w273 Andersson OK, Persson B, Hedner T, Aurell M, Wysocki M. Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men. *J Hypertens* 1989;**7**:465-469
- w274 Arosio E, Pancera P, Priante F, Ribul M, De Marchi S, Lechi A. Effects of sustained-release isradipine on blood pressure and peripheral hemodynamics in hypertensive patients. *Clin Ther* 1993;**15**:705-713
- w275 Arzilli E, Gandolfi E, Del Prato C, Innocenti P, Ponzanelli F, Gaiazza A, et al. Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study. *Eur J Clin Pharmacol* 1993;**44**:23-25
- w276 Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. *J Clin Pharmacol* 1995;**35**:239-243
- w277 Cl  roux J, Yardley C, Marshall A, Coulombe D, Lacourci  re Y. Antihypertensive and hemodynamic effects of calcium channel blockade with isradipine after acute exercise. *Am J Hypertens* 1992;**5**:84-87
- w278 Fogari R, Malacco E, Tettamanti F, Gnemmi AE, Milani M. Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring. *Br J Clin Pharmacol* 1993;**35**:51-54
- w279 Holmes DG. Isradipine: a slow-release formulation given once daily controls blood pressure for 24h. *Am J Hypertens* 1993;**6**:74S-76S
- w280 The Italian-Belgian Isradipine Study Group. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. *Am J Med* 1989;**86**:94-97
- w281 Kirch W, Burger KJ, Weidinger G, Welzel D. Efficacy and tolerability of the new calcium antagonist

- isradipine in essential hypertension. *J Cardiovasc Pharmacol* 1990;**15**(Suppl 1):S55-S59
- w282 Low CJS, Foy SG, Chaudhary H, Crozier IG, Baskaranathan S, Ikram H. Twenty-four hour profile of the anti-hypertensive action of isradipine in essential hypertension. *Blood Pressure* 1993;**2**:59-61
- w283 Nelson EB, Pool JL, Taylor AA. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist. *Clin Pharmacol Ther* 1986;**40**:694-7
- w284 O'Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H. Effect of isradipine on in-vivo platelet function. *Thromb Res* 1997;**86**:363-371
- w285 Rab SM, Mirza MA, Khan MH, Samad A, Ahmed M. Double-blind multicentre isradipine dose-confirmation study in Pakistan. *Drugs* 1990;**40**(Suppl 2):30-32
- w286 Simonsen K. Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension. *Am J Med* 1989;**86**:91-93
- w287 Staessen J, Lijnen P, Fagard R, Hespel P, Tan WP, Devos P, et al. Effects of the new calcium entry blocker isradipine (NP 200-110) in essential hypertension. *J Cardiovascular Pharmacol* 1989;**13**:271-276
- w288 Bremner AD, Fell PJ, Hosie J, James IGV, Saul PA, Taylor SH. Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. *J Hum Hypertens* 1993;**7**:79-81
- w289 Carr AA, Bottini PB, Prisant LM, Mulligan S, Devane JG, Fisher L, et al. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. *Am J Cardiol* 1992;**69**(SupplE):28E-32E
- w290 Corbin DOC, Wood DA, Macintyre CCA, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. *Eur Heart J* 1986;**7**:165-170
- w291 Eggertsen R, Hansson L. Effects of treatment with nifedipine and metoprolol in essential hypertension. *Eur J Clin Pharmacol* 1982;**21**:389-390
- w292 Feig PU, Gibson L, MacCarthy EP, Pettis PP, Schwartz L. The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. *Clin Ther* 1993;**15**:963-975
- w293 Handa K, Mori T, Tanaka H, Takada Y, Matsunaga A, Kiyonaga A, et al. Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects. *Cardiovasc Drugs Ther* 1992;**6**:85-90
- w294 Zanchetti A. The 24-hour efficacy of a new once-daily formulation of nifedipine. *Drugs* 1994;**48**:23-31
- w295 Landmark K, Dale J. Antihypertensive, haemodynamic and metabolic effects of nifedipine slow-release tablets in elderly patients. *Acta Medica Scandinavica* 1985;**218**:389-396
- w296 Ozenne G, Moore ND, Leprevost A, Tardif C, Boismare F, Pasquis P, et al. Nifedipine in chronic bronchial asthma: a randomised double-blind crossover trial against placebo. *Eur J Resp Dis* 1985;**67**:238-243
- w297 Patakas D, Maniki E, Tsāra V, Dascalōpōulou E. Nifedipine treatment of patients with bronchial asthma. *J Allergy Clin Immunol* 1987;**79**:959-963
- w298 Salvetti A, Virdis A, Taddei S, Ambrosoli S, Caiazza A, Gandolfi E, et al. Trough:peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: an Italian multicentre study. *J Hypertens* 1996;**14**:661-667
- w299 Sand J, Nordback I, Koskinen M, Matikainen M, Lindholm TS. Nifedipine for suspected type II sphincter of Oddi dyskinesia. *Am J Gastroenterol* 1993;**4**:530-535
- w300 De Simone G, Ferrara LA, Fasano ML, Di Lorenzo L, Lauria R. Slow-release nifedipine versus placebo in the treatment of arterial hypertension. *Jpn Heart J* 1985;**26**:219-225
- w301 Toal CB. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild to moderate hypertension. *Can J Cardiol* 1997;**13**:921-927
- w302 Zachariah PK, Schwartz GL, Sheps SG, Schirger A, Carlson CA, Moore AG. Antihypertensive effects of a new sustained release formulation of nifedipine. *J Clin Pharmacol* 1990;**30**:1012-1019
- w303 Harder S, Rietbrock S, Thürmann P. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. *Drug Res* 1994;**44**:133-136
- w304 Licata G, Scaglione R, Ganguzza A, Parrinello G, Costa R, Merlino G, et al. Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. *Eur J Clin Pharmacol* 1993;**45**:307-311
- w305 Lorimer AR, Smedsruud T, Walker P, Tyler HM. A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. *J Hum Hypertens* 1989;**3**:191-196
- w306 Lopez LM, Thorman AD, Mehta JL. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. *Am J Cardiol* 1990;**66**:1269-1271
- w307 Mehta JL, Lopez LM, Vlachakis ND, Gradman AH, Nash DT, O'Connell MT, et al. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. *Am Heart J* 1993;**125**:1704-1709
- w308 Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. *J Cardiovasc Pharmacol* 1988;**12**(Suppl 7):S79-84
- w309 Webster J, Robb OJ, Jeffers TA, Scott AK, Petrie JC, Towler HM. Once daily amlodipine in the treatment of mild to moderate hypertension. *Br J Clin Pharmacol* 1987;**24**:713-719
- w310 Frick MH, McGibney D, Tyler HM. Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension. *J Cardiovasc Pharmacol* 1988;**12**(Suppl 7):S76-S78
- w311 Ahmed JH, Elliott HL, Hosie J, Rafish E, Reid JL. Effects of nicardipine on the metabolic responses to food and exercise. *J Hum Hypertens* 1992;**6**:139-144
- w312 Bellett M, Pagny J-Y, Chatellier G, Corvol P, Ménard J. Evaluation of slow release nicardipine in essential hypertension by casual and ambulatory blood pressure measurements. Effects of acute versus chronic administration. *J Hypertens* 1987;**5**:599-604

- w313 Cox JP, Ryan J, O'Brien E, O'Malley K. The effect of slow-release nifedipine on ambulatory and clinic blood pressure in mild hypertension. *Br J Clin Pharmacol* 1989;**28**:79-82
- w314 Fagan TC, Tyler ED, Reitman MA, Kenley S, Weber MA. Sustained-release nifedipine in mild-to-moderate hypertension. *Chest* 1993;**104**:427-433
- w315 Mazzola C, Borgnino C, Colombo D, Lissoni F, Serra G, Turri DR, et al. Antihypertensive and hemodynamic effects of slow-release nifedipine. *Int J Clin Pharmacol Ther Toxicol* 1988;**26**:503-508
- w316 Salvetti A, Cardellino G, Pesenti M, Caiazza A, Ghisoni F, Del Prato C, et al. Antihypertensive effect of slow-release nifedipine. A placebo-controlled cross-over study. *Eur J Clin Pharmacol* 1989;**36**:439-442
- w317 Soro S, Cocca A, Pasanisi F, Tommaselli A, de Simone G, Costantino G, et al. The effects of nifedipine on sodium and calcium metabolism in hypertensive patients: a chronic study. *J Clin Pharmacol* 1990;**30**:133-137
- w318 Webster J, Petrie JC, Jeffers TA, Roy-Chaudhury P, Crichton W, Witte K, et al. Nifedipine sustained release in hypertension. *Br J Clin Pharmacol* 1991;**32**:433-439
- w319 Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. *J Hypertens* 1998;**16**:1831-1838
- w320 Opie LH, Müller FO, Myburgh DP, Rosendorff C, Sareli P, Seedat YK, et al. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension. *Am J Hypertens* 1997;**10**:250-260
- w321 Lijnen P, Petrov V. Blood pressure and cationic transport systems during combined calcium channel blocker and calcium administration in males. *Methods Find Exp Clin Pharmacol* 1996;**18**:287-294
- w322 Morris AD, Donnelly R, Connell JMC, Reid JL. Effects of the calcium antagonist lacidipine on insulin sensitivity in essential hypertension. *Horm Metab Res* 1994;**26**:257-259
- w323 Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. *J Cardiovasc Pharmacol* 1991;**17**(Suppl 4):S39-S44
- w324 Ueda S, Donnelly R, Panfilov V, Morris AD, Elliott HL. Lacidipine: effects on vascular pressure responses throughout the dosage interval in normotensive subjects. *Br J Clin Pharmacol* 1998;**46**:127-132
- w325 Lacourcière Y, Poirier L, Lefebvre J, Burford RG. Clinical efficacy of force titrated doses of diltiazem extended-release. *Am J Hypertens* 1995;**8**:282-286
- w326 Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, et al. A dose-response trial of once-daily diltiazem. *Am Heart J* 1992;**123**:1022-1026
- w327 Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, et al. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCL, in mature and elderly hypertensive patients. *Clin Ther* 1994;**16**:209-221
- w328 Dupont AG, Coupez JM, Jensen P, Coupez-Lopinot R, Schoors DF, Hermanns P, et al. Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension. *Cardiovasc Drugs Ther* 1991;**5**:701-708
- w329 Meeves SG, Park GD. The use of confidence intervals to describe the precision of trough/peak ratios for diltiazem CD in the treatment of hypertension. *J Clin Pharmacol* 1994;**34**:231-235
- w330 Meeves S, Hafner K, Park G, Weber M. Three-period crossover trial with ambulatory blood pressure monitoring for evaluating antihypertensive therapy. *Am Heart J* 1995;**130**:841-848
- w331 Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. *Am J Cardiol* 1985;**56**(supplH):86H-91H
- w332 Whelton A, Eff J, Magner DJ. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo controlled study with 24-hour ambulatory blood pressure monitoring. *J Clin Pharmacol* 1992;**32**:808-815
- w333 Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D. Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrochloride for the treatment of hypertension. *Clin Ther* 1992;**14**:148-157
- w334 Van Merode T, Van Bortel L, Smeets FAM, Böhm R, Mooij J, Rahn KH, et al. The effects of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients. *J Cardiovasc Pharmacol* 1990;**15**:109-113
- w335 Hedbäck B, Hermann LS. Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension. *Acta Medica Scandinavica Suppl* 1984;**681**:129-35
- w336 Kimose H-H, Bagger JP, Aagaard MT, Paulsen PK. Placebo-controlled, double-blind study of the effect of verapamil in intermittent claudication. *Angiology* 1990;**41**:595-598
- w337 Carr AA, Bottini PB, Prisant LM, Fisher LD, Devane JG, O'Brien DE, Rhoades RB. Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study. *J Clin Pharmacol* 1991;**31**:144-150
- w338 McMahon FG, Reder RF. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. *J Clin Pharmacol* 1989;**29**:1003-1007
- w339 Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. *Am Heart J* 1996;**132**:1202-1206
- w340 Corea L, Bentivoglio M, Berioli S, Bianchini C, Savino K, Sardina M. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind placebo-controlled study with 24-hour ambulatory blood pressure monitoring. *Cardiovascular Drugs Therapy* 1990;**4**:1501-1508

- w341 Lewis GRJ, Morley KD, Lewis BM, Bones PJ. The treatment of hypertension with verapamil. *NZ Med J* 1978;**87**:351-354
- w342 Van Bortel LMAB, Schiffers PMH, Böhm ROB, Mooij JMV, Rahn KH, Struyker Boudier HAJ. The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients. *Eur J Clin Pharmacol* 1990;**39**(Suppl 1):S39-S40
- w343 White WB, Anders RJ, MacIntyre JM, Black HR, Sica DA. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. *Am J Cardiol* 1995;**76**:375-380